Patents Assigned to TAKEDA VACCINES, INC.
-
Patent number: 9861691Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.Type: GrantFiled: July 10, 2015Date of Patent: January 9, 2018Assignee: Takeda Vaccines, Inc.Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
-
Patent number: 9834757Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.Type: GrantFiled: November 6, 2015Date of Patent: December 5, 2017Assignee: Takeda Vaccines, Inc.Inventors: Subash Chandra Das, Joseph David Santangelo, Dan Thomas Stinchcomb, Jorge E. Osorio
-
Patent number: 9821049Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.Type: GrantFiled: March 15, 2013Date of Patent: November 21, 2017Assignee: Takeda Vaccines, Inc.Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, Robert F. Bargatze, William Tino
-
Patent number: 9801934Abstract: The present invention relates to single dose parenteral vaccine compositions comprising mixtures of monovalent Norovirus virus-like particles. Methods of conferring protective immunity against Norovirus infections in a human subject by administering such compositions are also disclosed.Type: GrantFiled: March 15, 2013Date of Patent: October 31, 2017Assignee: TAKEDA VACCINES, INC.Inventors: Charles Richardson, Thomas R. Foubert
-
Patent number: 9783579Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: GrantFiled: March 13, 2014Date of Patent: October 10, 2017Assignees: Takeda Vaccines, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Dan T. Stinchcomb, Claire Kinney, Richard M Kinney, Jill A Livengood
-
Patent number: 9713638Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration.Type: GrantFiled: June 10, 2013Date of Patent: July 25, 2017Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
-
Patent number: 9518096Abstract: The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.Type: GrantFiled: July 25, 2014Date of Patent: December 13, 2016Assignee: TAKEDA VACCINES, INC.Inventors: Charles Richardson, Robert F. Bargatze, Joel Haynes, Bryan Steadman
-
Patent number: 9439959Abstract: Chimeric Influenza virus-like particles including gag polypeptides are described. Virus-like particles are generated with a gag polypeptide, a neuraminidase polypeptide and optionally a hemagglutinin polypeptide. Preferred methods of generation include expression in insect cells.Type: GrantFiled: July 27, 2007Date of Patent: September 13, 2016Assignee: TAKEDA VACCINES, INC.Inventor: Joel R. Haynes
-
Patent number: 9408901Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.Type: GrantFiled: November 8, 2013Date of Patent: August 9, 2016Assignees: TAKEDA VACCINES, INC, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH & HUMAN SERVICESInventors: Jill A. Livengood, Claire Y. Huang, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
-
Patent number: 9359410Abstract: Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.Type: GrantFiled: June 10, 2013Date of Patent: June 7, 2016Assignee: TAKEDA VACCINES INC.Inventors: Thomas S. Vedvick, Bryan Steadman, Charles Richardson, Thomas R. Foubert, Charles R. Petrie
-
Patent number: 9308249Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.Type: GrantFiled: March 15, 2013Date of Patent: April 12, 2016Assignee: TAKEDA VACCINES, INC.Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
-
Patent number: 9272028Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.Type: GrantFiled: March 15, 2013Date of Patent: March 1, 2016Assignee: TAKEDA VACCINES, INC.Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
-
Patent number: 9211323Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.Type: GrantFiled: May 28, 2010Date of Patent: December 15, 2015Assignee: TAKEDA VACCINES, INC.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
-
Publication number: 20150343046Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, attenuated or modified vaccinia virus vectors expressing enterobacterial-associated peptides. In other embodiments, vaccine compositions are reported of use in a subject.Type: ApplicationFiled: April 6, 2015Publication date: December 3, 2015Applicant: TAKEDA VACCINES, INC.Inventors: Dan T. STINCHCOMB, Jorge E. OSORIO, Timothy D. POWELL, Joseph N. BREWOO
-
Patent number: 9028809Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, attenuated or modified vaccinia virus vectors expressing enterobacterial-associated peptides. In other embodiments, vaccine compositions are reported of use in a subject.Type: GrantFiled: November 24, 2010Date of Patent: May 12, 2015Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Joseph N. Brewoo
-
Patent number: 9011874Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions. In other embodiments, vaccine compositions are reported of use in a subject.Type: GrantFiled: November 22, 2010Date of Patent: April 21, 2015Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Jeremy Jones
-
Patent number: 9005632Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions having two or more influenza gene segments. In other embodiments, vaccine compositions are reported of use in a subject.Type: GrantFiled: July 20, 2012Date of Patent: April 14, 2015Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Jeremy C. Jones, Joseph N. Brewoo
-
Patent number: 8980275Abstract: The present invention provides particle-forming chimeric proteins comprising a Calicivirus capsid protein and one or more heterologous antigen sequences. In particular, the present invention discloses engineered Calicivirus capsid protein sequences containing heterologous epitopes fused at internal locations such that the modified capsid proteins retain the ability to form virus-like particles when expressed in host cells. Virus-like particles comprising the chimeric proteins and vaccine formulations are also described.Type: GrantFiled: January 21, 2011Date of Patent: March 17, 2015Assignee: Takeda Vaccines, Inc.Inventors: Bryan Steadman, Ross Taylor
-
Patent number: 8968996Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration.Type: GrantFiled: June 10, 2012Date of Patent: March 3, 2015Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
-
Publication number: 20150023995Abstract: The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.Type: ApplicationFiled: July 25, 2014Publication date: January 22, 2015Applicant: TAKEDA VACCINES, INC.Inventors: Charles RICHARDSON, Robert F. BARGATZE, Joel HAYNES, Bryan STEADMAN